Ocular Therapeutix Price Target Raised To $30 From $20 At JMP Securities

Laboratory Test Tubes

Image Source: Unsplash

JMP Securities analyst Jonathan Wolleben raised the firm's price target on Ocular Therapeutix (OCUL) to $30 from $20 and reiterates an Outperform rating on the shares.

Ocular's supplemental new drug application submission for allergic conjunctivitis keeps Dextenza on track for potential approval in its first in-office indication in Q4 of 2021, Wolleben tells investors in a research note. The analyst thinks approval is likely and he looks for an FDA action date in October 2021.

He models sales of over $150M at peak penetration for allergic conjunctivitis and says the potential approval is a key development as it could benefit Ocular's dry eye candidates.


Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.